Letters from FDA underscore heated rivalry

11/8/2012 | Pharmalot.com

The FDA Office of Prescription Drug Promotion issued in October untitled letters to Cornerstone Therapeutics and ONY Pharmaceuticals for promoting their respective drugs for neonatal respiratory disease syndrome. The two drugmakers are cited by the FDA for making unsupported superiority claims and omitting risk information. The letters are a sign of what can happen when drugs are marketed at the expense of rivals, according to this article.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL